New Cell Cultureware Enhances Stem Cell Expansion
A new defined coated cell cultureware by denovoMATRIX allow for the serum-free expansion of mesenchymal stem cells.
A new product introduced by denovoMATRIX, a German company that develops and manufactures biomimetic coatings for cultivating human stem cells, enhances the expansion process for human mesenchymal stem cells (hMSC). The new product, myMATRIX MSC, promotes adhesion, proliferation, and high viability of hMSC. The novel surface of the product supports long-term expansion of hMSCs over 10 passages and more than 25 population doublings. Furthermore, myMATRIX MSC enables expansion of hMSC in both serum-free and xeno-free media conditions.
Due to their high accessibility and extensive beneficial properties, hMSC offer exciting promises in a plethora of applications in regenerative medicine, particularly in cell-based therapies. The major challenge of hMSC-based therapy is the large-scale expansion of cells in order to achieve the cell numbers necessary for therapeutic treatment.
Currently, bovine-derived fetal calf serum and human plasma-derived fibronectin are commonly used in hMSC culture. These biological extracts frequently reduce experimental reproducibility, however, and represent a liability for hMSC manufacturers. To increase lot-to-lot consistency and eliminate the risk of transmission of xenogenic infectious agents, defined cell culture conditions, including media and extracellular matrix mimetic coatings, are essential, according to the company.
denovoMATRIX launched the new cultureware in August 2019.
Source: denovoMATRIX
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
